<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30871133</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1256</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20061256</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) commonly produces herpangina, but fatal neurological complications have been observed in children. Enterovirus 71 (EV-A71) and Coxsackievirus 16 (CV-A16) are the predominant viruses causing HFMD worldwide. With rising concern about HFMD outbreaks, there is a need for an effective vaccine against EV-A71 and CV-A16. Although an inactivated vaccine has been developed against EV-A71 in China, the inability of the inactivated vaccine to confer protection against CV-A16 infection and other HFMD etiological agents, such as CV-A6 and CV-A10, necessitates the exploration of other vaccine platforms. Thus, the antigenic peptide-based vaccines are promising platforms to develop safe and efficacious multivalent vaccines, while the monoclonal antibodies are viable therapeutic and prophylactic agents against HFMD etiological agents. This article reviews the available information related to the antigenic peptides of the etiological agents of HFMD and their neutralizing antibodies that can provide a basis for the design of future therapies against HFMD etiological agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anasir</LastName><ForeName>Mohd Ishtiaq</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Centre for Virus and Vaccine Research, Sunway University, Bandar Sunway, Subang Jaya, Selangor 47500, Malaysia. ishtiaqa@sunway.edu.my.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poh</LastName><ForeName>Chit Laa</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0001-8475-6291</Identifier><AffiliationInfo><Affiliation>Centre for Virus and Vaccine Research, Sunway University, Bandar Sunway, Subang Jaya, Selangor 47500, Malaysia. pohcl@sunway.edu.my.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CVVR Research Budget</GrantID><Agency>Sunway University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antigenic peptide</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30871133</ArticleId><ArticleId IdType="pmc">PMC6471744</ArticleId><ArticleId IdType="doi">10.3390/ijms20061256</ArticleId><ArticleId IdType="pii">ijms20061256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., Liang Z. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum. Vaccin. Immunother. 2014;10:360&#x2013;367. doi: 10.4161/hv.27087.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., He S., Yan Q., Xu X., Wu W., Ge S., Zhang S., Chen M., Xia N. Severe hand, foot and mouth disease associated with coxsackievirus A10 infections in Xiamen, China in 2015. J. Clin. Virol. 2017;93:20&#x2013;24. doi: 10.1016/j.jcv.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.05.011</ArticleId><ArticleId IdType="pubmed">28577423</ArticleId></ArticleIdList></Reference><Reference><Citation>Anh N.T., Nhu L.N.T., Van H.M.T., Hong N.T.T., Thanh T.T., Hang V.T.T., Ny N.T.H., Nguyet L.A., Phuong T.T.L., Nhan L.N.T., et al. Emerging coxsackievirus A6 causing hand, foot and mouth disease, Vietnam. Emerg. Infect. Dis. 2018;24:654&#x2013;662. doi: 10.3201/eid2404.171298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2404.171298</ArticleId><ArticleId IdType="pmc">PMC5875260</ArticleId><ArticleId IdType="pubmed">29553326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Poh C.L. T cell immunity to enterovirus 71 infection in humans and implications for vaccine development. Int. J. Med. Sci. 2018;15:1143&#x2013;1152. doi: 10.7150/ijms.26450.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.26450</ArticleId><ArticleId IdType="pmc">PMC6097258</ArticleId><ArticleId IdType="pubmed">30123051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Yang H., Wang C., Yao X.J., Zhang H.L., Zhang R.L., He Y.Q. Genomic characteristics of coxsackievirus A8 strains associated with hand, foot, and mouth disease and herpangina. Arch. Virol. 2016;161:213&#x2013;217. doi: 10.1007/s00705-015-2646-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-015-2646-1</ArticleId><ArticleId IdType="pubmed">26483280</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Wu S., Xiong Y., Li T., Wen Z., Yan M., Qin K., Liu Y., Wu J. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS ONE. 2014;9:e96051. doi: 10.1371/journal.pone.0096051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096051</ArticleId><ArticleId IdType="pmc">PMC4002479</ArticleId><ArticleId IdType="pubmed">24776922</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S., Klemola P., Kaijalainen S., Paananen A., Simonen M.L., Vuorinen T., Roivainen M. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J. Clin. Virol. 2010;48:49&#x2013;54. doi: 10.1016/j.jcv.2010.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.02.002</ArticleId><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Bian L., Xu M., Liang Z. EV-A71 vaccine licensure: A first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg. Microbes Infect. 2016;5:e75. doi: 10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China. N. Engl. J. Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Mo Z., Liang Z., Zhang Y., Li R., Ong K.C., Wong K.T., Yang E., Che Y., Wang J., et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: A report of further observations. BMC Med. 2015;13:226. doi: 10.1186/s12916-015-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B.A., Pallansch M.A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39:195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R.J., Rossmann M.G. Crystal structure of human enterovirus 71. Science. 2012;336:1274. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler K.L., Yoder J.L., Carnegie M.S., Ashley R.E., Makhov A.M., Conway J.F., Hafenstein S. The enterovirus 71 A-particle forms a gateway to allow genome release: A cryoEM study of picornavirus uncoating. PLoS Pathog. 2013;9:e1003240. doi: 10.1371/annotation/e92d19e0-996a-4bfa-afdd-20dce770ed75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/e92d19e0-996a-4bfa-afdd-20dce770ed75</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnap D.M., Filman D.J., Trus B.L., Cheng N., Booy F.P., Conway J.F., Curry S., Hiremath C.N., Tsang S.K., Steven A.C., et al. Molecular tectonic model of virus structural transitions: The putative cell entry states of poliovirus. J. Virol. 2000;74:1342&#x2013;1354. doi: 10.1128/JVI.74.3.1342-1354.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.3.1342-1354.2000</ArticleId><ArticleId IdType="pmc">PMC111469</ArticleId><ArticleId IdType="pubmed">10627545</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G., Arnold E., Erickson J.W., Frankenberger E.A., Griffith J.P., Hecht H.J., Johnson J.E., Kamer G., Luo M., Mosser A.G., et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985;317:145&#x2013;153. doi: 10.1038/317145a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/317145a0</ArticleId><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill T.J., Bubeck D., Rowlands D.J., Hogle J.M. Characterization of early steps in the poliovirus infection process: Receptor-decorated liposomes induce conversion of the virus to membrane-anchored entry-intermediate particles. J. Virol. 2006;80:172&#x2013;180. doi: 10.1128/JVI.80.1.172-180.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.1.172-180.2006</ArticleId><ArticleId IdType="pmc">PMC1317540</ArticleId><ArticleId IdType="pubmed">16352541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng W., Ren J., Hu Z., Xu J., Lou Z., Li X., Yin W., Shen X., Porta C., et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., Xu K., Wang N., Cao L., Wu J., Gao Q., Fry E.E., Stuart D.I., Rao Z., Wang J., et al. Neutralization mechanisms of two highly potent antibodies against human enterovirus 71. mBio. 2018;9:e01013&#x2013;e01018. doi: 10.1128/mBio.01013-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01013-18</ArticleId><ArticleId IdType="pmc">PMC6030555</ArticleId><ArticleId IdType="pubmed">29970466</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., Guo M.S., Chow Y.H., Yang W.S., Chang K.H., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Yang L., Li Z., Ye X., Yu H., Zhao H., Li S., Yuan L., Qian H., et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci. Rep. 2015;5:12973. doi: 10.1038/srep12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12973</ArticleId><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="pubmed">26243660</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw-Yong K.L., Sam I.C., Koh M.T., Chan Y.F. Immunodominant IgM and IgG epitopes recognized by antibodies induced in enterovirus A71-associated Hand, Foot and Mouth Disease patients. PLoS ONE. 2016;11:e0165659. doi: 10.1371/journal.pone.0165659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165659</ArticleId><ArticleId IdType="pmc">PMC5091889</ArticleId><ArticleId IdType="pubmed">27806091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F., Wang Y.P., Mao Q.Y., Yao X., Liu S., Li F.X., Zhu F.C., Yang J.Y., Liang Z.L., Lu F.M., et al. Enterovirus 71 viral capsid protein linear epitopes: Identification and characterization. Virol. J. 2012;9:26. doi: 10.1186/1743-422X-9-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-26</ArticleId><ArticleId IdType="pmc">PMC3292509</ArticleId><ArticleId IdType="pubmed">22264266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T.K., Jia Q., Lim X.F., He F., Meng T., Chow V.T., Kwang J. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol. J. 2012;9:55. doi: 10.1186/1743-422X-9-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-55</ArticleId><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Li Z., Zheng J., Yang L., Yu M., Yu H., Chen Y., Que Y., Shih J.W., et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014;4:498&#x2013;513. doi: 10.7150/thno.7457.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.7457</ArticleId><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T.K., Jia Q., Meng T., Chow V.T., Kwang J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved &#x201c;knob&#x201d; region of VP3 protein. PLoS Negl. Trop. Dis. 2014;8:e2895. doi: 10.1371/journal.pntd.0002895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002895</ArticleId><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="pubmed">24875055</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Q., Ng Q., Chin W., Meng T., Chow V.T.K., Wang C.I., Kwang J., He F. Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity. Sci. Rep. 2017;7:46402. doi: 10.1038/srep46402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep46402</ArticleId><ArticleId IdType="pmc">PMC5395816</ArticleId><ArticleId IdType="pubmed">28422137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Bai Y., Liu W., Xiao X., Huang Y., Cen S., Chan P.K., Sun X., Sheng W., Zeng Y. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol. 2013;13:287. doi: 10.1186/1471-2180-13-287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-13-287</ArticleId><ArticleId IdType="pmc">PMC4029445</ArticleId><ArticleId IdType="pubmed">24320792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Guo M.S., Lin F.H., Hsiao K.N., Weng S.Y., Chou A.H., Wang J.R., Hsieh S.Y., Su I.J., Liu C.C. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE. 2012;7:e49973. doi: 10.1371/journal.pone.0049973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049973</ArticleId><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., Liu F., Shi J., Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30:6642&#x2013;6648. doi: 10.1016/j.vaccine.2012.08.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31:2130&#x2013;2136. doi: 10.1016/j.vaccine.2013.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Sun C., Xiao X., Pang L., Shen S., Zhang J., Cen S., Yang B.B., Huang Y., Sheng W., et al. Phage Display-Derived Cross-Reactive Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A16. Jpn. J. Infect. Dis. 2016;69:66&#x2013;74. doi: 10.7883/yoken.JJID.2015.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2015.060</ArticleId><ArticleId IdType="pubmed">26073737</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R., Xu L., Zheng Q., Cui Y., Li S., He M., Yin Z., Liu D., Li S., Li Z., et al. Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Sci. Adv. 2018;4 doi: 10.1126/sciadv.aat7459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aat7459</ArticleId><ArticleId IdType="pmc">PMC6155056</ArticleId><ArticleId IdType="pubmed">30255146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., Sun Y., Fan J., Zhu B., Cao L., Gao Q., Zhang Y., Liu H., Rao Z., Wang X. Structures of coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating. Nat. Commun. 2018;9:4985. doi: 10.1038/s41467-018-07531-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07531-0</ArticleId><ArticleId IdType="pmc">PMC6255764</ArticleId><ArticleId IdType="pubmed">30478256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Zheng Q., Li S., He M., Wu Y., Li Y., Zhu R., Yu H., Hong Q., Jiang J., et al. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat. Commun. 2017;8:505. doi: 10.1038/s41467-017-00477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00477-9</ArticleId><ArticleId IdType="pmc">PMC5593947</ArticleId><ArticleId IdType="pubmed">28894095</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Mao Q., Li S., Gao F., Zhao H., Liu Y., Wan J., Ye X., Xia N., Cheng T., et al. A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Res. 2016;134:50&#x2013;57. doi: 10.1016/j.antiviral.2016.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.08.025</ArticleId><ArticleId IdType="pubmed">27582066</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Joshi M.D., Singhania S., Ramsey K.H., Murthy A.K. Peptide vaccine: Progress and challenges. Vaccines. 2014;2:515&#x2013;536. doi: 10.3390/vaccines2030515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines2030515</ArticleId><ArticleId IdType="pmc">PMC4494216</ArticleId><ArticleId IdType="pubmed">26344743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirado S.M., Yoon K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16:69&#x2013;86. doi: 10.1089/088282403763635465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/088282403763635465</ArticleId><ArticleId IdType="pubmed">12725690</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J.F., Cao R.Y., Deng Y.Q., Tian X., Jiang T., Qin E.D., Qin C.F. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol. J. 2011;8:106. doi: 10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Chen I.C., Su L.Y., Huang K.J., Lei H.Y., Liu C.C. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin. Vaccine Immunol. 2010;17:1517&#x2013;1523. doi: 10.1128/CVI.00108-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00108-10</ArticleId><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen I.C., Wang S.M., Yu C.K., Liu C.C. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med. Microbiol. Immunol. 2013;202:259&#x2013;265. doi: 10.1007/s00430-013-0289-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-013-0289-y</ArticleId><ArticleId IdType="pubmed">23408291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R.Y., Dong D.Y., Liu R.J., Han J.F., Wang G.C., Zhao H., Li X.F., Deng Y.Q., Zhu S.Y., Wang X.Y., et al. Human IgG subclasses against enterovirus Type 71: Neutralization versus antibody dependent enhancement of infection. PLoS ONE. 2013;8:e64024. doi: 10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Alonso S., Chow V.T., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X., Su X., Li X., Li H., Li T., Zhou Z., Zhong T., Zhou R. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS ONE. 2012;7:e41381. doi: 10.1371/annotation/2da932d4-8654-45c8-bf83-7b3b09dbc146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/2da932d4-8654-45c8-bf83-7b3b09dbc146</ArticleId><ArticleId IdType="pmc">PMC3407240</ArticleId><ArticleId IdType="pubmed">22848478</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.X., Zhao H., Cao R.Y., Deng Y.Q., Han J.F., Zhu S.Y., Ma J., Liu L., Qin E.D., Qin C.F. Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice. Virol. J. 2014;11:79. doi: 10.1186/1743-422X-11-79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-11-79</ArticleId><ArticleId IdType="pmc">PMC4030048</ArticleId><ArticleId IdType="pubmed">24885030</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Penaranda S., Maher K., Pallansch M.A. Complete genome sequences of all members of the species Human enterovirus A. J. Gen. Virol. 2004;85:1597&#x2013;1607. doi: 10.1099/vir.0.79789-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Jiang L., Liang Z., Mao Q., Su W., Zhang H., Li X., Jin J., Xu L., Zhao D., et al. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum. Vaccin. Immunother. 2014;10:2885&#x2013;2895. doi: 10.4161/hv.29823.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29823</ArticleId><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan C., Ye X., Ku Z., Kong L., Liu Q., Xu C., Cong Y., Huang Z. Beta-propiolactone inactivation of coxsackievirus A16 induces structural alteration and surface modification of viral capsids. J. Virol. 2017;91 doi: 10.1128/JVI.00038-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00038-17</ArticleId><ArticleId IdType="pmc">PMC5375664</ArticleId><ArticleId IdType="pubmed">28148783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Li H.Y., Han J.F., Deng Y.Q., Zhu S.Y., Li X.F., Yang H.Q., Li Y.X., Zhang Y., Qin E.D., et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci. Rep. 2015;5:7878. doi: 10.1038/srep07878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07878</ArticleId><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J., Wang X., Zhu L., Hu Z., Gao Q., Yang P., Li X., Wang J., Shen X., Fry E.E., et al. Structures of coxsackievirus A16 capsids with native antigenicity: Implications for particle expansion, receptor binding, and immunogenicity. J. Virol. 2015;89:10500&#x2013;10511. doi: 10.1128/JVI.01102-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01102-15</ArticleId><ArticleId IdType="pmc">PMC4580203</ArticleId><ArticleId IdType="pubmed">26269176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J., Wang X., Hu Z., Gao Q., Sun Y., Li X., Porta C., Walter T.S., Gilbert R.J., Zhao Y., et al. Picornavirus uncoating intermediate captured in atomic detail. Nat. Commun. 2013;4:1929. doi: 10.1038/ncomms2889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2889</ArticleId><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., Wang G.C., He Y.L., Han J.F., Ye Q., Qin C.F., Chen R. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J. Biol. Chem. 2015;290:3198&#x2013;3208. doi: 10.1074/jbc.M114.624536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.624536</ArticleId><ArticleId IdType="pmc">PMC4318995</ArticleId><ArticleId IdType="pubmed">25492868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., He Y.L., Li H.Y., Chen R. Crystal structures of yeast-produced enterovirus 71 and enterovirus 71/coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease. J. Virol. 2015;89:6196&#x2013;6208. doi: 10.1128/JVI.00422-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="pubmed">25833050</ArticleId></ArticleIdList></Reference><Reference><Citation>Frietze K.M., Peabody D.S., Chackerian B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 2016;18:44&#x2013;49. doi: 10.1016/j.coviro.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.03.001</ArticleId><ArticleId IdType="pmc">PMC4983494</ArticleId><ArticleId IdType="pubmed">27039982</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmons B., Lim P.Y., Djurup R., Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine. 2018;36:6623&#x2013;6630. doi: 10.1016/j.vaccine.2018.09.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.062</ArticleId><ArticleId IdType="pubmed">30293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., Iwasaki T., Sata T., Wakita T., Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J. Virol. 2007;81:9386&#x2013;9395. doi: 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Cao R.Y., Chen R., Mo L., Han J.F., Wang X., Xu X., Jiang T., Deng Y.Q., Lyu K., et al. Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions. Proc. Natl. Acad. Sci. USA. 2013;110:7619&#x2013;7624. doi: 10.1073/pnas.1300233110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1300233110</ArticleId><ArticleId IdType="pmc">PMC3651461</ArticleId><ArticleId IdType="pubmed">23589862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Dai W., Zhang C., Zhou Y., Xiong P., Wang S., Ye X., Liu Q., Zhou D., Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg. Microbes Infect. 2018;7:94. doi: 10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhina E.A., Kuprianov V.V., Stepanova L.A., Tsybalova L.M., Kiselev O.I., Ravin N.V., Skryabin K.G. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. Virology. 2013;435:293&#x2013;300. doi: 10.1016/j.virol.2012.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.09.014</ArticleId><ArticleId IdType="pubmed">23062739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratz P.A., B&#xf6;ttcher B., Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. USA. 1999;96:1915&#x2013;1920. doi: 10.1073/pnas.96.5.1915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.5.1915</ArticleId><ArticleId IdType="pmc">PMC26711</ArticleId><ArticleId IdType="pubmed">10051569</ArticleId></ArticleIdList></Reference><Reference><Citation>Skamel C., Ploss M., Bottcher B., Stehle T., Wallich R., Simon M.M., Nassal M. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J. Biol. Chem. 2006;281:17474&#x2013;17481. doi: 10.1074/jbc.M513571200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M513571200</ArticleId><ArticleId IdType="pubmed">16621801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Zhu R., Xu L., Li Y., Li S., Yu H., Li S., Zhu H., Cheng T., Xia N. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine. 2017;35:2728&#x2013;2735. doi: 10.1016/j.vaccine.2017.03.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.065</ArticleId><ArticleId IdType="pubmed">28408118</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.Y., Lin J.J., Chiu C.H., Yang S., Tsao K.C., Huang Y.C., Lin T.Y. A Potent Virus-Specific Antibody-Secreting Cell Response to Acute Enterovirus 71 Infection in Children. J. Infect. Dis. 2015;212:808&#x2013;817. doi: 10.1093/infdis/jiv094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv094</ArticleId><ArticleId IdType="pubmed">25712974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.W., Liu C.C., Lin M.H., Ho H.M., Yang Y.T., Chow Y.H., Chong P., Sia C. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J. Virol. Methods. 2011;173:189&#x2013;195. doi: 10.1016/j.jviromet.2011.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.02.003</ArticleId><ArticleId IdType="pubmed">21315763</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.H., Ong K.C., Perera D., Wong K.T. A monoclonal antibody to ameliorate central nervous system infection and improve survival in a murine model of human Enterovirus-A71 encephalomyelitis. Antiviral Res. 2016;132:196&#x2013;203. doi: 10.1016/j.antiviral.2016.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.04.015</ArticleId><ArticleId IdType="pubmed">27340013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G.H., Luo Y.J., Wu X.Y., Si B.Y., Lin L., Zhu Q.Y. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol. J. 2010;7:106. doi: 10.1186/1743-422X-7-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-106</ArticleId><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim X.F., Jia Q., Khong W.X., Yan B., Premanand B., Alonso S., Chow V.T., Kwang J. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS ONE. 2012;7:e29751. doi: 10.1371/journal.pone.0029751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y.Q., Ma J., Xu L.J., Li Y.X., Zhao H., Han J.F., Tao J., Li X.F., Zhu S.Y., Qin E.D., et al. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71. Appl. Microbiol. Biotechnol. 2015;99:7663&#x2013;7671. doi: 10.1007/s00253-015-6652-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-015-6652-8</ArticleId><ArticleId IdType="pubmed">25967656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Cifuente J.O., Ashley R.E., Conway J.F., Makhov A.M., Tano Y., Shimizu H., Nishimura Y., Hafenstein S. A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J. Virol. 2013;87:11363&#x2013;11370. doi: 10.1128/JVI.01926-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01926-13</ArticleId><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T., Xianyu L., Lyu S. Monoclonal neutralizing antibodies against EV71 screened from mice immunized with yeast-produced virus-like particles. Virol. Sin. 2015;30:208&#x2013;213. doi: 10.1007/s12250-015-3573-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-015-3573-8</ArticleId><ArticleId IdType="pmc">PMC8200868</ArticleId><ArticleId IdType="pubmed">26040893</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Mao C., Ma S., Wang X., Sun Z., Yi Y., Guo M., Shen X., Sun L., Bi S. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem. Biophys. Res. Commun. 2009;390:1126&#x2013;1128. doi: 10.1016/j.bbrc.2009.09.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.09.103</ArticleId><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q., He F., Kwang J. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. Viruses. 2015;7:6441&#x2013;6457. doi: 10.3390/v7122949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122949</ArticleId><ArticleId IdType="pmc">PMC4690872</ArticleId><ArticleId IdType="pubmed">26670245</ArticleId></ArticleIdList></Reference><Reference><Citation>Almagro J., Fransson J. Humanization of antibodies. Front. Biosci. 2008;13:1619&#x2013;1633. doi: 10.2741/2786.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2786</ArticleId><ArticleId IdType="pubmed">17981654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Y.H., Kumar A., Liew C.W., Tharakaraman K., Srinivasaraghavan K., Sasisekharan R., Verma C., Lescar J. Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513. Sci. Rep. 2018;8:8449. doi: 10.1038/s41598-018-26800-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-26800-y</ArticleId><ArticleId IdType="pmc">PMC5981469</ArticleId><ArticleId IdType="pubmed">29855525</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Ng Q., Jia Q., Kwang J., He F. A Novel Humanized Antibody Neutralizes H5N1 Influenza Virus via Two Different Mechanisms. J. Virol. 2015;89:3712&#x2013;3722. doi: 10.1128/JVI.03014-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03014-14</ArticleId><ArticleId IdType="pmc">PMC4403434</ArticleId><ArticleId IdType="pubmed">25609802</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen N.S., Friesen R.H.E., Zhu X., Jongeneelen M., Blokland S., Vermond J., van Eijgen A., Tang C., van Diepen H., Obmolova G., et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science. 2018;362:598&#x2013;602. doi: 10.1126/science.aaq0620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaq0620</ArticleId><ArticleId IdType="pmc">PMC6241527</ArticleId><ArticleId IdType="pubmed">30385580</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>